References
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin2013 Jan;63(1):11-30.23335087
- Novara G, Ficarra V, Antonelli A, Artibani W, Bertini R, Carini M, et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol2010 Oct;58(4):588-95.10.1016/j.eururo.2010.07.006
- Fujioka T, Obara W, Committee for Establishment of the Clinical Practice Guideline for the Management of Renal Cell C, the Japanese Urological A. Evidence-based clinical practice guideline for renal cell carcinoma: the Japanese Urological Association 2011 update. Int J Urol2012 Jun;19(6):496-503.
- Bazarbashi S, Alkhateeb S, Abusamra A, Rabah D, Alotaibi M, Almansour M, et al. Saudi oncology society and Saudi urology association combined clinical management guidelines for renal cell carcinoma. Urol Ann2014 Oct;6(4):286-9.10.4103/0974-7796.14097425371602
- Bellmunt J, Puente J, Garcia de Muro J, Lainez N, Rodriguez C, Duran I, et al. SEOM clinical guidelines for the treatment of renal cell carcinoma. Clin Transl Oncol2014 Dec;16(12):1043-50.10.1007/s12094-014-1219-125274276
- Ljungberg B, Gudmundsson E, Christensen S, Lundstam S, Swedish Kidney Cancer Quality Register G. Practice patterns for the surgical treatment of T1 renal cell carcinoma: a nationwide population-based register study. Scand J Urol2014 Oct;48(5):445-52.10.3109/21681805.2014.898686
- Campbell L, Nuttall R, Griffiths D, Gumbleton M. Activated extracellular signal-regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma. Cancer2009 Aug 01;115(15):3457-67.10.1002/cncr.2438919526593
- Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw2009 Jun;7(6):618-30.1955558410.6004/jnccn.2009.0043
- Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol2016 Sep;27(suppl 5):v58-v68.
- Zekri J, Dreosti LM, Ghosn M, Hamada E, Jaloudi M, Khorshid O, et al. Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement. J Multidiscip Healthc2015;8:335-44.26251610
- Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, et al. Kidney cancer, version 3.2015. J Natl Compr Canc Netw2015 Feb;13(2):151-9.2569160610.6004/jnccn.2015.0022
- Zagouri F, Peroukidis S, Tzannis K, Kouloulias V, Bamias A, Hellenic Genito-Urinary Cancer G. Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: a systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG). Crit Rev Oncol Hematol2015 Jan;93(1):36-49.
- Bamias A, Escudier B, Sternberg CN, Zagouri F, Dellis A, Djavan B, et al. Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. Oncologist2017 Jun;22(6):667-79.10.1634/theoncologist.2016-043528592625
- Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol2016 Jul;70(1):93-105.2693555910.1016/j.eururo.2016.02.029
- Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol2010 Jun;17(6):1471-4.10.1245/s10434-010-0985-420180029
- Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol2001 Mar 15;19(6):1649-57.10.1200/JCO.2001.19.6.164911250993
- Rini B, Goddard A, Knezevic D, Maddala T, Zhou M, Aydin H, et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol2015 Jun;16(6):676-85.2597959510.1016/S1470-2045(15)70167-1
- Margulis V, Master VA, Cost NG, Leibovich BC, Joniau S, Kuczyk M, et al. International consultation on urologic diseases and the European Association of Urology international consultation on locally advanced renal cell carcinoma. Eur Urol2011 Oct;60(4):673-83.2175253310.1016/j.eururo.2011.06.042
- Aitchison M, Bray CA, Van Poppel H, Sylvester R, Graham J, Innes C, et al. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial. Eur J Cancer2014 Jan;50(1):70-7.24074763
- Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet2016 May 14;387(10032):2008-16.2696909010.1016/S0140-6736(16)00559-6
- Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med2016 Dec 08;375(23):2246-54.10.1056/NEJMoa161140627718781
- Robert J. Motzer NBH, Frede Donskov, Marine Gross-Goupil, Sergei Varlamov, Evgeny Kopyltsov, Jae-Lyun Lee, Bohuslav Melichar, Brian I. Rini, Toni K. Choueiri, Milada Zemanova, Lori A Wood, Dirk Fahlenkamp, Martin Neil Reaume, Arnulf Stenzl, Weichao Bao, Paola Aimone, Christian Doehn, Paul Russo, Cora N. Sternberg. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT). ASCO, J Clin Oncol 35, 2017 (suppl; abstr 4507)2017.
- Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, et al. Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma. Eur Urol2017 May;71(5):719-22.2798636910.1016/j.eururo.2016.11.034
- Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol2004 Mar;171(3):1071-6.10.1097/01.ju.0000110610.61545.ae14767273
- Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet2007 Dec 22;370(9605):2103-11.10.1016/S0140-6736(07)61904-718156031
- Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med2007 Jan 11;356(2):115-24.1721552910.1056/NEJMoa065044
- Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol2010 Feb 20;28(6):1061-8.10.1200/JCO.2009.23.976420100962
- Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol2017 Feb 20;35(6):591-7.2819981810.1200/JCO.2016.70.7398
- Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med2007 May 31;356(22):2271-81.1753808610.1056/NEJMoa066838
- Hess G, Borker R, Fonseca E. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting. Clin Genitourin Cancer2013 Jun;11(2):161-7.10.1016/j.clgc.2012.10.003
- Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, et al. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer2014 Apr 15;110(8):1917-22.2469142510.1038/bjc.2014.25
- Escudier B, Albiges L, Blesius A, Loriot Y, Massard C, Fizazi K. How to select targeted therapy in renal cell cancer. Ann Oncol2010 Oct;21 Suppl 7:vii59-62.
- Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med2015 Nov 05;373(19):1814-23.2640615010.1056/NEJMoa1510016
- Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol2016 Jul;17(7):917-27.10.1016/S1470-2045(16)30107-327279544
- Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med2015 Nov 05;373(19):1803-13.2640614810.1056/NEJMoa1510665
- Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, et al. Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy. Eur Urol2016 Jan;69(1):4-6.2650831210.1016/j.eururo.2015.10.017
- Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol2014 Mar;15(3):286-96.10.1016/S1470-2045(14)70030-024556040
- Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol2014 Sep 01;32(25):2765-72.2504933010.1200/JCO.2013.54.6911
- Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol2016 Mar;17(3):378-88.10.1016/S1470-2045(15)00515-X
- Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol2016 May;69(5):866-74.10.1016/j.eururo.2015.10.04926626617